Q-omics provides the consensus-scored WIZP1 profile across patient tissues and cancer cell-line models. WIZP1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, WIZP1 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, WIZP1 RNA expression shows 9,434 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRP, and TGCT as cancer lineages where WIZP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WIZP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WIZP1 survival associations across molecular data types. WIZP1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WIZP1 RNA expression–survival associations across cancer types. High WIZP1 expression shows unfavorable associations in DLBC, THCA, SKCM and STAD, but favorable associations in KIRC and ESCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for WIZP1 RNA expression.
This table summarizes WIZP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for WIZP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WIZP1 shows higher tumor expression in KIRP, HNSC and LIHC. The KIRP box plot shows higher WIZP1 RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .022).
This table shows molecular features associated with WIZP1 in patient tissues and cancer cell lines. In patient samples, WIZP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
